KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Purchases 43,707 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 43,707 shares of KalVista Pharmaceuticals stock in a transaction dated Thursday, January 30th. The stock was acquired at an average price of $8.76 per share, for a total transaction of $382,873.32. Following the completion of the transaction, the insider now owns 4,986,480 shares in the company, valued at approximately $43,681,564.80. The trade was a 0.88 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 3rd, Venrock Healthcare Capital Par bought 14,562 shares of KalVista Pharmaceuticals stock. The stock was bought at an average price of $9.22 per share, for a total transaction of $134,261.64.

KalVista Pharmaceuticals Stock Down 4.4 %

KalVista Pharmaceuticals stock traded down $0.42 during midday trading on Friday, hitting $9.20. The company's stock had a trading volume of 303,808 shares, compared to its average volume of 293,376. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $16.88. The stock's 50-day moving average price is $8.80 and its 200-day moving average price is $10.76. The company has a market capitalization of $454.66 million, a PE ratio of -2.53 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.01. As a group, equities analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on KALV. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an "outperform" rating and a $19.00 target price for the company. Needham & Company LLC restated a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Cantor Fitzgerald reiterated an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. Finally, TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a "buy" rating and a $30.00 target price for the company. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $23.80.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of KalVista Pharmaceuticals by 67.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company's stock valued at $96,000 after purchasing an additional 3,328 shares in the last quarter. Intech Investment Management LLC acquired a new stake in KalVista Pharmaceuticals during the 3rd quarter worth about $126,000. SG Americas Securities LLC purchased a new position in KalVista Pharmaceuticals during the 3rd quarter valued at about $153,000. Quest Partners LLC acquired a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $175,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company's stock worth $182,000 after purchasing an additional 3,314 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).